Essity divests Russian operations

STOCKHOLM, June 10, 2023 /PRNewswire/ — The hygiene and health company Essity divests its operations in Russia. Essity has signed an agreement with a buyer and the transaction has now been approved by the Russian authorities. The transaction is expected to be finalized during the second quarter of 2023. Essity began work in April 2022 to … Read more

Menarini Group predstavila na kongrese Európskej hematologickej asociácie údaje o podskupine NEXPOVIO® (selinexor) zo štúdie BOSTON, ktoré poukazujú na klinický potenciál preparátu pri recidivujúcom/refraktérnom mnohopočetnom myelóme USA – slovenčina USA – English USA – English USA – español USA – Deutsch USA – Pусский USA – Français USA – Polski USA – čeština

Údaje ukazujú významné 71 % zníženie rizika progresie ochorenia alebo úmrtia v skupine selinexor + bortezomib + dexametazón (SVd) v porovnaní so skupinou bortezomib + dexametazón (Vd) pri pacientoch bez predchádzajúcej liečby inhibítormi proteazómu (PI)  Údaje ukazujú významné 47 % zníženie rizika úmrtia pri SVd v porovnaní s Vd pri pacientoch s mnohopočetným myelómom, ktorí … Read more

Essity divests Russian operations

STOCKHOLM, June 10, 2023 /PRNewswire/ — The hygiene and health company Essity divests its operations in Russia. Essity has signed an agreement with a buyer and the transaction has now been approved by the Russian authorities. The transaction is expected to be finalized during the second quarter of 2023. Essity began work in April 2022 to … Read more

FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer’s disease

STOCKHOLM, June 10, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai’s Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI® (lecanemab-irmb) 100 … Read more

FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer’s disease

STOCKHOLM, June 10, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai’s Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI® (lecanemab-irmb) 100 … Read more

Knife attack, murder, rape… a large study highlights the trauma of violent crime investigators

the essential All the elements relating to the appalling attack in Annecy will be examined at length by police analysts. The profound psychological impact this work has on them is underestimated. This article was not written by the editorial staff of La Dépêche du Midi, but taken from the partner site The Conversation. This June … Read more

Cancer: the superpower of the colon to fight against metastases, a major Toulouse discovery

the essential A research team from the Toulouse Oncopole has just shown that the intestine is capable of fighting against metastases thanks to a family of T lymphocytes found only in the colon. The journal Science Immunology has just published this major discovery which opens up new hopes in the fight against cancer. In scientific … Read more

Qi gong and Taï-Chi in Ehpad

Since 2021, residents of the Ehpad of the Villefranche hospital center “Le Jardin Fleuri”, Rulhe site and “Le Bosquet”, Chartreuse site, have benefited from Qigong lessons. This traditional Chinese gymnastics is based on breathing, slow movements have a beneficial influence on psychological function, improve coordination, mobility, range of motion and balance, and have a beneficial … Read more